Analyst Price Target is $0.85
▲ +58.94% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MariMed in the last 3 months. The average price target is $0.85, with a high forecast of $0.85 and a low forecast of $0.85. The average price target represents a 58.94% upside from the last price of $0.53.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in MariMed.
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.